Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel treatments for hematological and musculoskeletal disorders. The company's product pipeline consists of KER-050, KER-047and KER-012 which are in clinical stage. Keros Therapeutics, Inc. is based in LEXINGTON, MA.
| Revenue (Most Recent Fiscal Year) | $244.06M |
| Net Income (Most Recent Fiscal Year) | $-187.35M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 7.57 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.72 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.60 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | 28.84% |
| Net Margin (Trailing 12 Months) | 35.65% |
| Return on Equity (Trailing 12 Months) | 12.20% |
| Return on Assets (Trailing 12 Months) | 11.43% |
| Current Ratio (Most Recent Fiscal Quarter) | 29.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 29.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $14.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.86 |
| Earnings per Share (Most Recent Fiscal Year) | $2.30 |
| Diluted Earnings per Share (Trailing 12 Months) | $1.82 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 30.47M |
| Free Float | 24.19M |
| Market Capitalization | $419.52M |
| Average Volume (Last 20 Days) | 0.30M |
| Beta (Past 60 Months) | 0.87 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 71.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |